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Background: Few studies have compared the response to growth hormone (GH) treatment between indications
such as isolated growth hormone deficiency (IGHD), born small for gestational age (SGA), idiopathic short stature
(ISS), and multiple pituitary hormone deficiency (MPHD). The aim of this analysis of data, collected from two large
ongoing observational outcome studies, was to evaluate growth and insulin-like growth factor-I (IGF-I) response
data for children of short stature with IGHD, MPHD, SGA, or ISS following two years of treatment with the
recombinant GH product NorditropinW (Novo Nordisk A/S, Bagsværd, Denmark).
Methods: Analysis of auxologic data from two ongoing prospective observational studies, NordiNetW International
Outcomes Study (NordiNetW IOS) and NovoNetW/American NorditropinW Studies: Web-enabled Research (ANSWER)
ProgramW.
Results: 4,582 children aged <18 years were included: IGHD, n = 3,298; SGA, n = 678; ISS, n = 334; and MPHD,
n = 272. After two years’ GH treatment, change in height standard deviation score (SDS) was +1.03 in SGA and
+0.84 in ISS vs. +0.97 in IGHD (p = 0.047; p< 0.001 vs. IGHD, respectively). Height gain was comparable between
IGHD and MPHD. In pre-pubertal children vs. total population, height SDS change after two years was: IGHD, +1.24
vs. +0.97; SGA, +1.17 vs. +1.03; ISS, +1.04 vs. +0.84; and MPHD, +1.16 vs. +0.99 (all p< 0.001).
Conclusions: After two years’ GH treatment, change in height SDS was greater in SGA and less in ISS, compared
with IGHD; the discrepancy in responses may be due to the disease nature or confounders (i.e. age). Height SDS
increase was greatest in pre-pubertal children, supporting early treatment initiation to optimize growth outcomes.
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Growth hormone (GH) treatment is approved for treat-
ment of short stature in a number of childhood diagno-
ses, such as isolated growth hormone deficiency (IGHD)
and multiple pituitary hormone deficiency (MPHD).
There are other childhood indications, which are not
associated with a deficiency of endogenous growth hor-
mone that can be improved by GH treatment, for in-
stance, born small for gestational age (SGA) and
idiopathic short stature (ISS) [1,2]. Growth hormone
treatment has been shown to increase final adult height
in each of these patient populations [3-12]. Moreover, in
patients with IGHD, total gain in height SDS was
reported to correlate significantly with pre-pubertal gain
in height SDS, with younger age at treatment start being
a significant predictor of greater treatment response
[13,14].
Few studies have directly compared the growth
response to GH treatment according to diagnosis
and pubertal stage. Some studies suggest that pre-
pubertal children with ISS experience less gain in
height with GH treatment than short children with
growth hormone deficiency [15,16]. The growth re-
sponse has, however, not been compared in large,
observational real-life studies across indications and
pubertal stage.
Treatment outcomes that can be achieved in daily
clinical practice may differ widely from the more con-
trolled setting of randomized trials; therefore, post-
marketing surveillance studies are required to generate
data from large cohorts about the efficacy (and/or
safety) of an intervention in the real-world clinical
setting, which may then be used to inform changes in
indications. While there are obvious advantages to
the data provided by observational studies, there
are also a number of drawbacks that arise from the
necessity of having a heterogeneous, all-comer study
population; these include, but are not limited to, non-
standardization of laboratory tests, treatment dose
and number of injections, missing parameters (e.g.
mid-parental height, target height, birth weight),
and variation in local practices when studies are
multinational.
The aim of this analysis of data, collected from two
large ongoing observational outcome studies, was to
evaluate growth and insulin-like growth factor-I (IGF-
I) response data for children of short stature with
IGHD, MPHD, SGA, or ISS following two years of
treatment with the recombinant GH product Norditro-
pinW (Novo Nordisk A/S, Bagsværd, Denmark). A sec-
ondary focus was to assess the impact of GH therapy
in pre-pubertal children compared with the total
patient population within each of the indications
investigated.Methods
Data for this analysis were obtained from the NordiNetW
International Outcome Study (IOS; NCT00960128)
launched in 2006 and ongoing in 19 countries (Czech Re-
public, Denmark, Finland, France, Germany, Hungary,
Ireland, Israel, Italy, Lithuania, Montenegro, Netherlands,
Norway, Russia, Serbia, Slovenia, Sweden, Switzerland,
UK), and from the US observational study NovoNetW/
American NorditropinW Studies: Web-enabled Research
(ANSWER) ProgramW (NCT01009905), which began in
2002 and is also ongoing. The IOS and the ANSWER
ProgramW use a similar electronic platform, NordiNetW/
NovoNetW, to collect and manage data about the effect-
iveness and safety of NorditropinW in normal clinical
practice. Physicians enter data on patient history, phys-
ical examinations, and treatment regimens using the
web-based NordiNetW/NovoNetW tool.
The use of NorditropinW for patients included in these
large observational studies is at the discretion of the par-
ticipating physicians as part of their routine clinical
practice. Both observational studies are operated in ac-
cordance with the Declaration of Helsinki and with the
approval of local institutional review boards.
Data are anonymized in the two observational studies.
For all patients, physicians measure a number of vari-
ables at the initial visit according to their standard med-
ical practice, including baseline height, weight, bone age,
Tanner stage or testicular volume, maximum stimulated
serum GH concentration, and serum IGF-I concentra-
tions. At follow-up visits, data gathered include GH dose
and injection frequency, height, weight, Tanner stage or
testicular volume, and IGF-I levels, among other
variables.
For this analysis, only patients aged <18 years with
data collected at baseline AND at both one and two year
follow-up visits (±3 months) were included. Data were
divided by indication based on investigators’ clinical
diagnosis (IGHD, MPHD, SGA, and ISS), gender, and
pubertal status. Patients with IGHD were used as the
reference group because this population represents the
optimal indication for replacement GH treatment, where
it is unlikely that other hormone deficiencies act as con-
founders for outcomes; in addition, there exists a large
quantity of efficacy and safety data for GH treatment in
IGHD. For this study, the pre-pubertal population group
was defined using descriptions of clinical puberty symp-
toms: girls had Tanner stage 1 breast development, while
boys had a testicular volume <4 mL. Children were
identified as pre-pubertal when they remained at this
stage of development for the entire two-year follow-up
period. To be identified as pre-pubertal when informa-
tion on pubertal status was lacking, girls had to be no
more than 6 years of age, while boys had to be no more
than 7 years old at the start of the observational period;
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unlikely to start puberty during the observational period,
because mean age −2 SD at start of puberty in the
observed patient population was ~8 years for girls and
~9 years for boys.
For all patients included in this analysis, height SDS at
baseline and change in height SDS at two years were cal-
culated. For patients in the NovoNetW/ANSWER Pro-
gramW study, height SDS was determined according to
standard formulas provided by the Center for Disease
Control and Prevention [17], and for patients in the
NordiNetW IOS study by the corresponding country
references. Bone age was determined manually or with
the automatic software application BoneXpertW, which is
included in the NordiNetW, but not in the NovoNetW
system. When laboratory IGF-I measurements were
available, IGF-I SDS values were calculated according to
established age- and sex-specific reference values and
models [18] without adjustments for local differences in
laboratory procedures or possible variations in IGF-I
levels.
Statistical analysis
Descriptive statistics and a simple analysis of variance
(ANOVA) model were used to analyze combined patient
data from the NordiNetW IOS and the NovoNetW/AN-
SWER ProgramW. Variables examined included change
in height SDS and change in IGF-I SDS. Analyses were
made both on the total population and on the sub-
population of pre-pubertal patients within each indica-
tion. No adjustment for multiplicity of testing was done.
Differences were regarded as statistically significant if
the p-value was <0.05. All analyses were performed with
SAS software, version 9.1 (SAS Institute Inc., Cary, NC,
USA).
Results
Baseline characteristics
NordiNetW IOS and NovoNetW/ANSWER ProgramW
have yielded data on >11,000 and >11,500 NorditropinW-
treated patients, respectively, most of whom were children
with a variety of diagnoses, treated for short stature. For
this analysis, 4,582 pediatric patients (i.e. the total popula-
tion in this analysis) with the following indications and
with two years of follow-up data were identified in the
databases: IGHD, n=3,298; SGA, n=678; ISS, n=334;
and MPHD, n=272. Mean age at treatment start was
10.2, 7.9, 10.9, and 7.9 years for IGHD, SGA, ISS, and
MPHD, respectively (Table 1). Children born SGA had the
lowest baseline height SDS of −3.1. Mean bone age was
delayed relative to chronological age across all indications,
ranging from −1.6 to −1.8 years. With the exception of
children born SGA who had a mean IGF-I SDS of −0.7,
mean values for IGF-I SDS were below −1.5 SDS for allindications at baseline. Mean GH doses by indication
ranged from 0.036 (MPHD) to 0.049 (ISS) mg/kg/day
(Table 1).
The percentage of pre-pubertal children in each indi-
cation group varied: ISS, 23%; IGHD, 34%; MPHD, 61%;
and SGA, 64%. In comparison with the total population,
the mean height SDS was lower for pre-pubertal chil-
dren, although mean IGF-I SDS was higher in this
group.
Change in height
In the total patient population, the mean change in
height SDS at one year for all indications was +0.57 SDS
or higher, except among children with ISS (+0.49 SDS;
Figure 1). At one year, children with MPHD and chil-
dren born SGA, responded with height SDS of +0.67
and +0.64, respectively; these height gains were +0.10
and +0.07 SDS greater than in children with IGHD
(p = 0.001 for both). In contrast, height gain at one year
with GH treatment in ISS was −0.08 SDS lower than
that in IGHD (p = 0.005).
At two years of GH treatment, mean change in height
from baseline was +0.99 vs. +0.97 SDS for patients with
MPHD and IGHD, respectively, but was +1.03 SDS for
patients born SGA (p = 0.047 vs. IGHD) and +0.84 for
patients with ISS (p< 0.001 vs. IGHD). Normal height
for age and gender (within ±2 SDS) was reached in 78%
(IGHD), 45% (SGA), 76% (ISS), and 79% (MPHD) of
children. Across all indications, 73% of patients reached
normal height after two years of treatment.
In pre-pubertal children, the gains in height SDS at
one year, and two years, were higher than in the total
population (Figure 1). Among pre-pubertal children at
one year, gain in height SDS did not differ significantly
between IGHD and any other indication. At two years,
the gain in height was above +1 SDS for all indications
and comparable, except for in ISS compared with in
IGHD (+1.04 vs. +1.24 SDS, p = 0.03) (Figure 1). Normal
height was reached in 73% (IGHD), 46% (SGA), 72%
(ISS), and 75% (MPHD) of children at two years in the
pre-pubertal population.
Change in IGF-I SDS
The mean change in IGF-I SDS for the total population
was greater than +2 SDS after one and two years of GH
treatment in all indications, except in children born
SGA at one year (Figure 2). Mean values stayed within
the reference range (±2 SDS) throughout the study. At
two years, mean IGF-I SDS was 0.80 (IGHD), 1.15
(SGA), 1.06 (ISS), and 0.58 (MPHD). At one and two
years of treatment, children born SGA had a signifi-
cantly lower IGF-I increase than children with IGHD
(+1.80 vs. +2.36 SDS, and +2.00 vs. +2.57 SDS, respect-
ively, p< 0.001).
Table 1 Baseline characteristics and mean GH dose during two-year treatment period for total and pre-pubertal patient population by indication
Children with IGHD Children born SGA Children with ISS Children with MPHD
Total Pre-pubertal Total Pre-pubertal Total Pre-pubertal Total Pre-pubertal
Total N (pre-pubertal % of
total indication)
3,298 1,120 (34%) 678 434 (64%) 334 76 (23%) 272 165 (61%)
Male gender, N (%) 2,444 (74%) 778 (70%) 396 (58%) 274 (63%) 240 (72%) 59 (78%) 171 (63%) 106 (64%)
Mean chronological
age ± SD (years)
10.2 ± 3.6 6.5 ± 2.8 7.9 ± 3.2 6.1 ± 2.1 10.9 ± 2.9 7.1 ± 2.3 7.9 ± 4.9 4.8 ± 3.5
Mean height SDS± SD −2.3 ± 1.0 −2.7 ± 1.0 −3.1 ± 0.9 −3.3 ± 0.9 −2.3 ± 0.8 −2.6 ± 0.9 −2.0 ± 1.5 −2.3 ± 1.6
Mean bone age delay from
chronological age ± SD
(years) [N]
−1.8 ± 1.4 [2,419] −1.9 ± 1.3 [703] −1.6 ± 1.4 [430] −1.6 ± 1.2 [266] −1.7 ± 1.5 [294] −1.9 ± 1.4 [65] −1.7 ± 1.8 [137] −1.3 ± 1.7 [63]
Mean IGF-I SDS± SD [N] −1.8 ± 1.7 [2,784] −1.4 ± 1.4 [890] −0.7 ± 1.6 [434] −0.5 ± 1.4 [276] −1.6 ± 1.7 [308] −1.2 ± 1.4 [66] −1.9 ± 2.2 [222] −1.4 ± 1.9 [133]
Mean GH dose during two-year
treatment period ± SD
(mg/kg/day) [N]
0.042 ± 0.013 [3,272] 0.038 ± 0.011 [1,110] 0.042 ± 0.013 [678] 0.041 ± 0.013 [434] 0.049 ± 0.012 [334] 0.046 ± 0.011 [76] 0.036 ± 0.013 [268] 0.035 ± 0.011 [163]
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Figure 1 Mean height SDS at baseline, one year and two years and change in height SDS at one year and two years by indication.
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only exceeded +2 SDS for ISS at 1 year (Figure 2). Be-
tween indications, no significant differences were
observed in change in IGF-I SDS after either one or two
years of GH treatment. Mean values for IGF-I SDS in
pre-pubertal children were within the reference range for
the two-year period, as in the total patient populationsFigure 2 Mean IGF-I SDS at baseline, one year and two years by indic(Figure 2). At two years, mean IGF-I SDS was 0.45
(IGHD), 1.13 (SGA), 0.61 (ISS), and 0.65 (MPHD).
Discussion
This analysis of international data from two large on-
going observational studies (NordiNetW IOS and Novo-
NetW/ANSWER ProgramW) is, to our knowledge, theation.
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tween children with IGHD and children with MPHD,
SGA, and ISS treated with GH. In the total patient
population, the two-year change in height SDS was ap-
proximately +1 SDS for each indication investigated.
While the positive treatment responses for children with
MPHD and children born SGA exceeded the change in
height for children with IGHD at one year, only children
born SGA had a higher response compared with IGHD
after two years; these results are similar to those from
other studies comparing outcomes with GH treatment
in these indications [5,13,19]. It should be noted that al-
though height change was expressed in SDS, which is
generally considered more robust across gender and age
than using change in cm, change in height SDS is not
completely age-independent, because less variation is
observed in height SD in younger vs. older ages [20].
This may, to a small degree, contribute to our finding
that children with MPHD and those born SGA who
were considerably younger at GH treatment start (mean
7.9 years) had a better growth response compared with
IGHD (mean age of 10.2 years at treatment start). How-
ever, a positive effect of early age for growth hormone
response is suggested as reported by others [5,13,19,21-
25]. Among pre-pubertal children, where the differences
in age were less, children with MPHD and children born
SGA showed no significant difference in height gain
compared with IGHD.
After two years of GH treatment, more than 75% of
children with IGHD, MPHD, and ISS reached their nor-
mal height range (above −2 SDS). In contrast, although
children born SGA experienced the highest growth re-
sponse, only 45% reached normal height because their
baseline height was considerably lower than any other
group. The severe short stature of children born SGA
observed in this study can be partially explained by the
labeling in Europe, where patients must be below −2.5
SDS before treatment is initiated, and in France, where
medical reimbursement is possible only if children born
SGA are less than or equal to −3 SDS at treatment start.
Pre-pubertal children born SGA had the smallest in-
crease in IGF-I SDS of all pre-pubertal indications, but
had the highest baseline levels. A positive correlation
has been proposed between increasing IGF-I levels and
height increase in pre-pubertal children [26]. The results
of our study appear to lend some support to this hypoth-
esis, because pre-pubertal children in all other indica-
tions than ISS had comparable increases in IGF-SDS and
height SDS.
The smallest two-year height SDS increase occurred in
children with ISS (+0.84 SDS), which was significantly
lower compared with IGHD. Several factors could have
influenced the lower height increase seen in children
with ISS: (a) age, the children with ISS in this study hada higher mean age at the start of GH treatment com-
pared with the other indications investigated. Other
studies have shown higher age at treatment initiation to
be negatively associated with growth in children receiv-
ing GH, including ISS [16,21]; (b) pubertal status, the
ISS group had the lowest percentage of pre-pubertal
children (23%) (see later for discussion); (c) the variable
etiology of the disease, because the diagnosis of ISS is
based upon short stature due to a variety of unknown
causes [27]. In our analysis, among the four indications,
children with ISS had the highest mean age in the pre-
pubertal subgroup (7.1 years at baseline) and a male
gender dominance (78%), with bone age less or equally
delayed in ISS compared with the three other indications
studied (Table 1), which could suggest an underlying dis-
order of constitutional growth delay; d) lastly, in the
total population, in spite of a higher GH dose given in
ISS, the two-year IGF-I change was comparable between
ISS and IGHD, while height gain was less in ISS. At
baseline, IGF-I deficiency was less in ISS than in IGHD.
These facts suggest some degree of GH or IGF-I insensi-
tivity in ISS compared with IGHD, possibly influenced
by differences in underlying disease nature, age, gender,
and/or pubertal stage. Other studies support a degree of
insensitivity to IGF-I in children with ISS [15,28], with
the wide range of growth responses to GH in this patient
population being consistent with the broad spectrum of
genetic and molecular defects that result in IGF-I in-
sensitivity [27].
Few other studies have compared the growth and/or
IGF-I response to GH treatment between GHD and ISS.
In a two-year, open-label trial, 63 children with GHD
and 102 children with ISS were randomized to receive
GH therapy based on an IGF-I target of 0 SDS, +2 SDS,
or a dosing corresponding to the patient’s weight [15].
Children with GHD grew more than those with ISS in
both IGF-targeted dosage groups despite having similar
IGF-I levels. In the +2 SDS target group, the mean
(±SD) change in height SDS for children with GHD was
2.04 (±0.17) compared with 1.33 (±0.09) for children
with ISS. In the 0 SDS target group, the change in
heights SDS results were 1.41 (±0.13) and 0.84 (±0.07),
respectively. The results of a smaller clinical study com-
paring GHD with ISS were similar [16]. In spite of the
real-life, heterogeneous nature of the observational stud-
ies reported here, our finding was consistent with a
reduced growth response in ISS. However, all indications
in this analysis surpassed the one-year response thresh-
old for GH efficacy, which is generally considered to be
approximately +0.25–0.5 SDS for change in height
[2,22,29], thus demonstrating the ability of GH to stimu-
late linear growth regardless of indication.
For children with a variety of short stature indications,
the height SDS at the onset of puberty correlates
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Correlations with adult height were not examined in this
analysis, but pubertal status was found to have a marked
influence on growth by both one and two years of treat-
ment. In pre-pubertal children of all indication groups
the change in height SDS was greater than in the total
population, consistent with the preliminary two-year
findings from the NovoNetW/ANSWER ProgramW [19],
whose entirely US patient population overlapped with
US patients included in this study when two-year growth
data were available.
Further long-term follow-up with adult height data is
needed to be able to describe fully the benefits of start-
ing GH treatment early, especially in real-life situations,
although long-term safety data on modern growth hor-
mone therapy are generally reassuring [31]. To provide
high-quality long term data, it is important to monitor
the outcome of the populations in large observation-
al studies, such as NordiNetW IOS and NovoNetW/
ANSWER ProgramW, to assess the effectiveness and
safety of GH therapy in children, especially in non-GHD
indications.
Examining data from clinical practice contained in
large observational studies like NordiNetW IOS and
NovoNetW/ANSWER ProgramW can provide insights
into optimal treatments in actual clinical practice, such
as the desirability of starting growth hormone therapy
before puberty observed in this study. It must, however,
be considered that the differences in patient populations,
diagnostic and treatment practices between countries
represented in this large combined database may influ-
ence the outcome of any analysis. In particular, the
results for IGF-I shown here should be treated with cau-
tion due to the lack of information on assay and control
over local laboratory measurements and possible differ-
ences in normal IGF-I levels within the international pa-
tient cohort. Furthermore, although only a small
variation was observed in mean GH dose in the total
population across indications and also between the total
population and pre-pubertal groups, it should be noted
that dose recommendations for these indications vary
from country to country and, indeed, even within-
country variation in prescribing habits is likely. Lastly,
selection bias from the entire cohort of children receiv-
ing GH treatment for any of the four indications studied
could not be excluded; for example, drop outs could not
be systematically analyzed.
Conclusion
After two years of GH treatment, short children born
SGA showed a greater height response than children
with IGHD and MPHD (who experienced comparable
growth responses), while children with ISS had a slightly
lower response, possibly owing to confounders and/ordifferences in disease nature. Despite showing the great-
est SDS height response, a lower number of SGA chil-
dren reached a normal height range (above −2 SDS for
mean) at the end of the two-year period due to their low
baseline height. More than 75% of children with IGHD,
ISS, and MPHD achieved a normal height range after
two years of treatment. Beginning treatment at least two
years before the onset of puberty was associated with an
improved height gain, which suggests that GH treatment
should start well in advance of puberty to optimize
height growth outcomes.
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